PMV Pharma Cash Decreases to $112.9 Million
As of December 31, 2025, PMV Pharma had $112.9 million in cash, cash equivalents, and marketable securities, compared to $183.3 million at December 31, 2024. Net cash used in operations was $73.6 million for the year ended December 31, 2025, compared to $51.3 million for the year ended December 31, 2024.
Trade with 70% Backtested Accuracy
Analyst Views on PMVP
About PMVP
About the author
PMV Pharmaceuticals Reports 2025 Financial Results and Future Milestones
- Deteriorating Financials: PMV Pharmaceuticals reported a net loss of $77.7 million for 2025, translating to $1.48 per share, which is a significant increase from the previous year's loss of $58.7 million, highlighting the high costs associated with clinical-stage operations and R&D investments.
- Cash Flow Outlook: As of December 31, 2025, PMV had $112.9 million in cash and equivalents, down from $183.3 million the prior year, indicating increased financial pressure with an expected runway until the second quarter of 2027.
- Clinical Trial Progress: The ongoing PYNNACLE trial is evaluating Rezatapopt's efficacy in patients with TP53 Y220C mutations, with preliminary results showing a 50% overall response rate in ovarian cancer patients, suggesting promising clinical potential.
- FDA Fast Track Designation: In March 2026, the FDA granted Fast Track designation and Orphan Drug status to Rezatapopt for treating TP53 Y220C positive ovarian cancer, indicating significant market potential, with plans to submit a New Drug Application in Q1 2027.
PMV Pharmaceuticals Reports FY 2025 Earnings Beat Expectations
- Earnings Beat: PMV Pharmaceuticals reported a FY 2025 GAAP EPS of -$1.48, exceeding expectations by $0.06, indicating some resilience in financial performance despite ongoing losses.
- Cash Position: As of December 31, 2025, PMV Pharma had $112.9 million in cash, cash equivalents, and marketable securities, a significant decline from $183.3 million in 2024, reflecting pressure on the company's financial management.
- Operational Cash Usage: The net cash used in operations for FY 2025 was $73.6 million, a 42.8% increase from $51.3 million in 2024, suggesting greater challenges in operational expenditures that could impact future liquidity.
- Widening Net Loss: The net loss for FY 2025 was $77.7 million, up 32.3% from $58.7 million in 2024, which may raise investor concerns about the company's ongoing profitability and affect market confidence.
PMV Pharmaceuticals Reveals New Interim Data on Rezatapopt Monotherapy from Ongoing PYNNACLE Phase 2 Trial for Various Solid Tumors with TP53 Y220C Mutation
Clinical Trial Results: Updated data from the Phase 2 PYNNACLE trial presented at the 2025 AACR-NCI-EORTC Conference showed a 34% overall response rate (ORR) across eight tumor types, with a notable 46% ORR in the ovarian cancer cohort.
Rezatapopt Overview: Rezatapopt (PC14586) is a first-in-class small molecule designed to reactivate the p53 protein in tumors with the TP53 Y220C mutation, with plans for a New Drug Application submission for platinum-resistant ovarian cancer in Q1 2027.
Safety Profile: The treatment was generally well-tolerated, with most adverse events being Grade 1-2, and a low discontinuation rate due to treatment-related adverse events (3.6%).
Future Directions: PMV Pharma aims to continue generating data to support regulatory strategies and enhance treatment options for patients with advanced solid tumors harboring the TP53 Y220C mutation.
PMV Pharmaceuticals' Small-Cap Cancer Drug Demonstrates Verified Efficacy Across 8 Tumor Types
Clinical Trial Results: PMV Pharmaceuticals released interim data from the Phase 2 PYNNACLE trial, showing a 33% overall response rate for rezatapopt in patients with advanced solid tumors harboring the TP53 Y220C mutation, with notable efficacy in ovarian (43% ORR) and endometrial (60% ORR) cancers.
Safety and Regulatory Plans: The treatment was generally well-tolerated, with most adverse events being mild. PMV Pharma plans to enroll additional patients for a New Drug Application (NDA) for platinum-resistant/refractory ovarian cancer by early 2027, following FDA feedback.
PMV Pharma Announces Encouraging Interim Results from Phase 2 PYNNACLE Trial
Positive Interim Data: PMV Pharmaceuticals announced positive interim results from the Phase 2 portion of the PYNNACLE study, showing a 33% overall response rate in patients with advanced solid tumors, particularly those with TP53 Y220C mutations and KRAS wild-type.
Ovarian Cancer Focus: The study reported a 43% response rate in the ovarian cancer cohort, with a median duration of response of 7.6 months, and the company plans to submit a New Drug Application for rezatapopt in platinum resistant/refractory ovarian cancer by Q1 2027.
Insider Sale: General Counsel & COO of $PMVP Sells 23,151 Shares
Insider Trading Activity: Robert Ticktin, General Counsel & COO of $PMVP, sold 23,151 shares of the company, representing about 19% of his holdings, and now owns 98,695 shares. In the past six months, there have been four insider sales with no purchases.
Institutional Investor Movements: In the latest quarter, 10 institutional investors increased their positions in $PMVP stock while 48 reduced theirs, indicating mixed sentiment among institutional stakeholders.
PMV Pharmaceuticals Reports 2025 Financial Results and Future Milestones
- Deteriorating Financials: PMV Pharmaceuticals reported a net loss of $77.7 million for 2025, translating to $1.48 per share, which is a significant increase from the previous year's loss of $58.7 million, highlighting the high costs associated with clinical-stage operations and R&D investments.
- Cash Flow Outlook: As of December 31, 2025, PMV had $112.9 million in cash and equivalents, down from $183.3 million the prior year, indicating increased financial pressure with an expected runway until the second quarter of 2027.
- Clinical Trial Progress: The ongoing PYNNACLE trial is evaluating Rezatapopt's efficacy in patients with TP53 Y220C mutations, with preliminary results showing a 50% overall response rate in ovarian cancer patients, suggesting promising clinical potential.
- FDA Fast Track Designation: In March 2026, the FDA granted Fast Track designation and Orphan Drug status to Rezatapopt for treating TP53 Y220C positive ovarian cancer, indicating significant market potential, with plans to submit a New Drug Application in Q1 2027.
PMV Pharmaceuticals Reports FY 2025 Earnings Beat Expectations
- Earnings Beat: PMV Pharmaceuticals reported a FY 2025 GAAP EPS of -$1.48, exceeding expectations by $0.06, indicating some resilience in financial performance despite ongoing losses.
- Cash Position: As of December 31, 2025, PMV Pharma had $112.9 million in cash, cash equivalents, and marketable securities, a significant decline from $183.3 million in 2024, reflecting pressure on the company's financial management.
- Operational Cash Usage: The net cash used in operations for FY 2025 was $73.6 million, a 42.8% increase from $51.3 million in 2024, suggesting greater challenges in operational expenditures that could impact future liquidity.
- Widening Net Loss: The net loss for FY 2025 was $77.7 million, up 32.3% from $58.7 million in 2024, which may raise investor concerns about the company's ongoing profitability and affect market confidence.
PMV Pharmaceuticals Reveals New Interim Data on Rezatapopt Monotherapy from Ongoing PYNNACLE Phase 2 Trial for Various Solid Tumors with TP53 Y220C Mutation
Clinical Trial Results: Updated data from the Phase 2 PYNNACLE trial presented at the 2025 AACR-NCI-EORTC Conference showed a 34% overall response rate (ORR) across eight tumor types, with a notable 46% ORR in the ovarian cancer cohort.
Rezatapopt Overview: Rezatapopt (PC14586) is a first-in-class small molecule designed to reactivate the p53 protein in tumors with the TP53 Y220C mutation, with plans for a New Drug Application submission for platinum-resistant ovarian cancer in Q1 2027.
Safety Profile: The treatment was generally well-tolerated, with most adverse events being Grade 1-2, and a low discontinuation rate due to treatment-related adverse events (3.6%).
Future Directions: PMV Pharma aims to continue generating data to support regulatory strategies and enhance treatment options for patients with advanced solid tumors harboring the TP53 Y220C mutation.
PMV Pharmaceuticals' Small-Cap Cancer Drug Demonstrates Verified Efficacy Across 8 Tumor Types
Clinical Trial Results: PMV Pharmaceuticals released interim data from the Phase 2 PYNNACLE trial, showing a 33% overall response rate for rezatapopt in patients with advanced solid tumors harboring the TP53 Y220C mutation, with notable efficacy in ovarian (43% ORR) and endometrial (60% ORR) cancers.
Safety and Regulatory Plans: The treatment was generally well-tolerated, with most adverse events being mild. PMV Pharma plans to enroll additional patients for a New Drug Application (NDA) for platinum-resistant/refractory ovarian cancer by early 2027, following FDA feedback.
PMV Pharma Announces Encouraging Interim Results from Phase 2 PYNNACLE Trial
Positive Interim Data: PMV Pharmaceuticals announced positive interim results from the Phase 2 portion of the PYNNACLE study, showing a 33% overall response rate in patients with advanced solid tumors, particularly those with TP53 Y220C mutations and KRAS wild-type.
Ovarian Cancer Focus: The study reported a 43% response rate in the ovarian cancer cohort, with a median duration of response of 7.6 months, and the company plans to submit a New Drug Application for rezatapopt in platinum resistant/refractory ovarian cancer by Q1 2027.
Insider Sale: General Counsel & COO of $PMVP Sells 23,151 Shares
Insider Trading Activity: Robert Ticktin, General Counsel & COO of $PMVP, sold 23,151 shares of the company, representing about 19% of his holdings, and now owns 98,695 shares. In the past six months, there have been four insider sales with no purchases.
Institutional Investor Movements: In the latest quarter, 10 institutional investors increased their positions in $PMVP stock while 48 reduced theirs, indicating mixed sentiment among institutional stakeholders.
